FDA approves Padcev for urothelial cancer

The FDA granted accelerated approval to enfortumab vedotin-ejfv for treatment of adults with locally advanced or metastatic urothelial cancer, the agent’s developers announced in a press release.The approval applies to use of enfortumab vedotin-ejfv (Padcev; Astellas, Seattle Genetics) by patients who previously received a PD-1/PD-L1 inhibitor and a platinum-containing chemotherapy before

Read the full article here

Related Articles